` MDP (Medexus Pharmaceuticals Inc) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

MDP
vs
S&P TSX Composite Index (Canada)

Over the past 12 months, MDP has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of 91% compared to the S&P TSX Composite Index (Canada)'s 23% growth.

Stocks Performance
MDP vs S&P TSX Composite Index (Canada)

Loading
MDP
S&P TSX Composite Index (Canada)
Add Stock
www.alphaspread.com

Performance Gap
MDP vs S&P TSX Composite Index (Canada)

Loading
MDP
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
MDP vs S&P TSX Composite Index (Canada)

Loading
MDP
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Medexus Pharmaceuticals Inc vs Peers

S&P TSX Composite Index (Canada)
MDP
LLY
JNJ
NOVO B
ROG
Add Stock

Medexus Pharmaceuticals Inc
Glance View

Market Cap
104.2m CAD
Industry
Pharmaceuticals

Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.

MDP Intrinsic Value
7.63 CAD
Undervaluation 58%
Intrinsic Value
Price
Back to Top